Rapid antipsychotic response with ziprasidone predicts subsequent acute
manic/mixed episode remission.
Author(s): Ketter TA, Agid O, Kapur S, Loebel A, Siu CO, Romano SJ.
Affiliation(s): Department of Psychiatry and Behavioral Sciences, Stanford University, Stanford,
CA 94305-5723, USA. tketter@stanford.edu
Publication date & source: 2010, J Psychiatr Res. , 44(1):8-14
OBJECTIVE: To assess rapid antipsychotic efficacy with oral ziprasidone
monotherapy in bipolar acute manic/mixed episodes with psychotic features, and
predictive value of rapid antipsychotic response for subsequent acute manic/mixed
episode remission.
METHODS: Pooled analysis of two 3-week, randomized, double-blind,
placebo-controlled trials of ziprasidone (40-160mg/d) in inpatients with bipolar
I disorder, and a current manic or mixed episode, with (n=152) or without (n=246)
psychotic features. Psychosis improvement was evaluated by change in SADS-C
psychosis score (sum of delusions, hallucinations, and suspiciousness items).
Rapid antipsychotic response (>or=50% decrease in SADS-C psychosis score by Day
4) and acute manic episode response and remission (endpoint >or=50% MRS decrease,
and a MRS score
|